Why Study the T1D Remission Phase in the Pediatric Population?

Overview

Journal J Pediatr (Rio J)

Specialty Pediatrics

Date 2024 Dec 19

PMID 39701549

Authors

Jesper Johannesen

Affiliations

Soon will be listed here.

References

Nathan D, Genuth S, Lachin J, Cleary P, Crofford O, Davis M . The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. N Engl J Med. 1993; 329(14):977-86. DOI: 10.1056/NEJM199309303291401. View

Stiller C, Dupre J, Gent M, Heinrichs D, Jenner M, Keown P . Effects of cyclosporine in recent-onset juvenile type 1 diabetes: impact of age and duration of disease. J Pediatr. 1987; 111(6 Pt 2):1069-72. DOI: 10.1016/s0022-3476(87)80058-6. View

Paul D, Teschendorff A, Dang M, Lowe R, Hawa M, Ecker S . Increased DNA methylation variability in type 1 diabetes across three immune effector cell types. Nat Commun. 2016; 7:13555. PMC: 5141286. DOI: 10.1038/ncomms13555. View

Jeyam A, Colhoun H, McGurnaghan S, Blackbourn L, McDonald T, Palmer C . Clinical Impact of Residual C-Peptide Secretion in Type 1 Diabetes on Glycemia and Microvascular Complications. Diabetes Care. 2020; 44(2):390-398. DOI: 10.2337/dc20-0567. View

Rewers M, Ludvigsson J . Environmental risk factors for type 1 diabetes. Lancet. 2016; 387(10035):2340-2348. PMC: 5571740. DOI: 10.1016/S0140-6736(16)30507-4. View

Forlenza G, McVean J, Beck R, Bauza C, Bailey R, Buckingham B . Effect of Verapamil on Pancreatic Beta Cell Function in Newly Diagnosed Pediatric Type 1 Diabetes: A Randomized Clinical Trial. JAMA. 2023; 329(12):990-999. PMC: 9960020. DOI: 10.1001/jama.2023.2064. View

Krogvold L, Mynarek I, Ponzi E, Mork F, Hessel T, Roald T . Pleconaril and ribavirin in new-onset type 1 diabetes: a phase 2 randomized trial. Nat Med. 2023; 29(11):2902-2908. PMC: 10667091. DOI: 10.1038/s41591-023-02576-1. View

Coutinho A, Chapman K . The anti-inflammatory and immunosuppressive effects of glucocorticoids, recent developments and mechanistic insights. Mol Cell Endocrinol. 2010; 335(1):2-13. PMC: 3047790. DOI: 10.1016/j.mce.2010.04.005. View

Shapiro A, Lakey J, Ryan E, Korbutt G, Toth E, Warnock G . Islet transplantation in seven patients with type 1 diabetes mellitus using a glucocorticoid-free immunosuppressive regimen. N Engl J Med. 2000; 343(4):230-8. DOI: 10.1056/NEJM200007273430401. View

10.

Mork F, Madsen J, Jensen A, Hall G, Pilgaard K, Pociot F . Differences in insulin sensitivity in the partial remission phase of childhood type 1 diabetes; a longitudinal cohort study. Diabet Med. 2021; 39(2):e14702. DOI: 10.1111/dme.14702. View

11.

Marcovecchio M, Hendriks A, Delfin C, Battelino T, Danne T, Evans M . The INNODIA Type 1 Diabetes Natural History Study: a European cohort of newly diagnosed children, adolescents and adults. Diabetologia. 2024; 67(6):995-1008. PMC: 11058619. DOI: 10.1007/s00125-024-06124-5. View

12.

Kuo T, McQueen A, Chen T, Wang J . Regulation of Glucose Homeostasis by Glucocorticoids. Adv Exp Med Biol. 2015; 872:99-126. PMC: 6185996. DOI: 10.1007/978-1-4939-2895-8_5. View

13.

Ramos M, Leao I, Vezzani J, Campos L, Luescher J, Berardo R . An analysis of the remission phase in type 1 diabetes within a multiethnic Brazilian sample. J Pediatr (Rio J). 2024; 101(2):167-171. PMC: 11889658. DOI: 10.1016/j.jped.2024.09.005. View

14.

Dufort M, Greenbaum C, Speake C, Linsley P . Cell type-specific immune phenotypes predict loss of insulin secretion in new-onset type 1 diabetes. JCI Insight. 2019; 4(4). PMC: 6478408. DOI: 10.1172/jci.insight.125556. View

15.

Wherrett D, Chiang J, Delamater A, DiMeglio L, Gitelman S, Gottlieb P . Defining pathways for development of disease-modifying therapies in children with type 1 diabetes: a consensus report. Diabetes Care. 2015; 38(10):1975-85. PMC: 4876737. DOI: 10.2337/dc15-1429. View